[5-phosphodiesterase inhibitors and cardiovascular risk].

important predictors of erectile dysfunction. Am J Epidemiol 1994;140:930—7. [7] Roumeguère Th, Wespes E, Carpentier Y, Hoffmann P, Schulman CC. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003;44:355—9. [8] Ponholzer A, Temml C, Obermayr R, Wehrberger C, Madersbacher S. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke ? Eur Urol 2005;48:512—8. [9] Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the ‘‘Tip of the iceberg’’ of a systemic vascular disorder ? Eur Urol 2003;44:352—4. [10] Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP). JAMA. 2001;285:2486—2497. [11] Walldius G, Jungner I, Hölme I, et al. High apolipoprotein B, low apolipoprotein A-1 and improvement in the prediction of fatal myocardial infarction (Amoris study): a prospective study. Lancet 2001;358:2026—33. [12] Rosano G, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2006;47:214—22. [13] Feldman H, Johannes C, Derby C, Kleinman K, Mohr B, Araujo B, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000;30:328—38. [14] Solomon H, Man JW, Wierzbkicki AS, et al. Erectile dysfunction: cardiovascular risk and the role of the cardiologist. Int J Clin Pract 2003;57:96—9. [15] Ballantyne CM, Hoogeveen RC. Role of lipid and lipoprotein profiles in risk assessment and therapy. Am Heart J 2003;146:227—33. [16] Gotto Jr AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air force/Texas coronary atherosclerosis prevention study. Circulation 2000;101:477—84. [17] Solomon H, Wierzbicki AS, Lumb PJ, Lambert-Hammill M, Jackson G. Cardiovascular risk factors determine erectile and arterial function response to sildenafil. Am J Hypertens 2006;19:915—9. [18] Morishima A, Ohkubo N, Maeda N, Miki T, Mitsuda N. NFkappaB regulates plasma apolipoprotein A-I and high-density lipoprotein cholesterol through inhibition of peroxisome proliferatoractivated receptor alpha. J Biol Chem 2003;278:38188—93. [19] Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. Evidence for the involvement of an inhibitory-kappaB/nuclear factor-kappaBsensitive pathway in alveolar epithelial cells. J Pharmacol Exp Ther 2002;300:567—76. [20] Hughes TA, Stentz F, Gettys T, Smith SR. Combining betaadrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjects. Metabolism 2006;55:26—34. [21] Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented artery disease. Eur Urol 2003;44:360—5.